Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin Anti-inflammatory Effects Following PCI
NCT07292909Phase 4Recruiting
- Sponsor
- Hôtel-Dieu de France
- Start
- Sep 2025
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in coronary artery disease (CAD), sponsored by Hôtel-Dieu de France. Started Sep 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07292909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292909.